PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22729928-6 2013 When SSCs are exposed to the lifespan-enhancing drug rapamycin in vivo, the resultant HDAC gene expression patterns are opposite of those seen in the differentiating and aging SSCs, with increased Hdac2, Hdac6, and Sirt1 and decreased Hdac8, Hdac9, and Sirt4. Sirolimus 53-62 histone deacetylase 9 Homo sapiens 86-90 24395633-3 2014 Against this background, we report a dramatic response in a young patient with advanced HL refractory to the standard treatment who responded to the combination of a pan-histone deacetylase inhibitor (vorinostat, suberoylanilide hydroxamic acid, SAHA) and mammalian target of rapamycin (mTOR) inhibitor therapy (sirolimus,rapamume). Sirolimus 312-321 histone deacetylase 9 Homo sapiens 170-189 22729928-6 2013 When SSCs are exposed to the lifespan-enhancing drug rapamycin in vivo, the resultant HDAC gene expression patterns are opposite of those seen in the differentiating and aging SSCs, with increased Hdac2, Hdac6, and Sirt1 and decreased Hdac8, Hdac9, and Sirt4. Sirolimus 53-62 histone deacetylase 9 Homo sapiens 242-247 30050079-7 2018 Furthermore, co-inhibition of mTORC1 and HDAC with rapamycin and valproic acid, but neither alone, reproducibly promoted ESR1 expression in TNBC cells. Sirolimus 51-60 histone deacetylase 9 Homo sapiens 41-45 28993730-8 2017 However, targeting the altered biological pathways (mTOR, PDGFRB, FGF2, HDAC) guided identification of possibly beneficial treatment with a combination of sirolimus, thalidomide, sunitinib, and vorinostat. Sirolimus 155-164 histone deacetylase 9 Homo sapiens 72-76